NPM1 and acute lymphoblastic leukemia: DSP-5336 is a small molecule currently under phase I/II clinical development (DSP-5336-101 trial) enrolling adult patients with R/R AML or ALL and dose-expansion cohorts enrolling patients with R/R AML with KMT2Ar or NPM1-m.